Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Fibroblast activation protein (FAP) as a novel metabolic target.

Sánchez-Garrido MA, Habegger KM, Clemmensen C, Holleman C, Müller TD, Perez-Tilve D, Li P, Agrawal AS, Finan B, Drucker DJ, Tschöp MH, DiMarchi RD, Kharitonenkov A.

Mol Metab. 2016 Jul 16;5(10):1015-24. doi: 10.1016/j.molmet.2016.07.003. eCollection 2016 Oct.

2.

Scaffold-Free Coculture Spheroids of Human Colonic Adenocarcinoma Cells and Normal Colonic Fibroblasts Promote Tumorigenicity in Nude Mice.

Park JI, Lee J, Kwon JL, Park HB, Lee SY, Kim JY, Sung J, Kim JM, Song KS, Kim KH.

Transl Oncol. 2016 Feb;9(1):79-88. doi: 10.1016/j.tranon.2015.12.001.

3.

A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice.

Fang J, Xiao L, Joo KI, Liu Y, Zhang C, Liu S, Conti PS, Li Z, Wang P.

Int J Cancer. 2016 Feb 15;138(4):1013-23. doi: 10.1002/ijc.29831. Epub 2015 Sep 14.

4.

Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations.

Koczorowska MM, Tholen S, Bucher F, Lutz L, Kizhakkedathu JN, De Wever O, Wellner UF, Biniossek ML, Stahl A, Lassmann S, Schilling O.

Mol Oncol. 2016 Jan;10(1):40-58. doi: 10.1016/j.molonc.2015.08.001. Epub 2015 Aug 11.

5.

The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2).

Tsai CY, Liebig JK, Tsigelny IF, Howell SB.

Metallomics. 2015 Nov;7(11):1477-87. doi: 10.1039/c5mt00131e. Epub 2015 Jul 24.

6.

Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Jackson KW, Christiansen VJ, Yadav VR, Silasi-Mansat R, Lupu F, Awasthi V, Zhang RR, McKee PA.

Neoplasia. 2015 Jan;17(1):43-54. doi: 10.1016/j.neo.2014.11.002.

7.

Deficiency of fibroblast activation protein alpha ameliorates cartilage destruction in inflammatory destructive arthritis.

Wäldele S, Koers-Wunrau C, Beckmann D, Korb-Pap A, Wehmeyer C, Pap T, Dankbar B.

Arthritis Res Ther. 2015 Jan 20;17:12. doi: 10.1186/s13075-015-0524-6.

8.

Fibroblast activation protein α in tumor microenvironment: recent progression and implications (review).

Zi F, He J, He D, Li Y, Yang L, Cai Z.

Mol Med Rep. 2015 May;11(5):3203-11. doi: 10.3892/mmr.2015.3197. Epub 2015 Jan 14. Review.

9.

Fibroblast heterogeneity in the cancer wound.

Öhlund D, Elyada E, Tuveson D.

J Exp Med. 2014 Jul 28;211(8):1503-23. doi: 10.1084/jem.20140692. Review.

10.

Targeting nucleophosmin 1 represents a rational strategy for radiation sensitization.

Sekhar KR, Benamar M, Venkateswaran A, Sasi S, Penthala NR, Crooks PA, Hann SR, Geng L, Balusu R, Abbas T, Freeman ML.

Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1106-14. doi: 10.1016/j.ijrobp.2014.04.012. Epub 2014 Jul 8.

11.

Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.

Jansen K, Heirbaut L, Cheng JD, Joossens J, Ryabtsova O, Cos P, Maes L, Lambeir AM, De Meester I, Augustyns K, Van der Veken P.

ACS Med Chem Lett. 2013 Mar 18;4(5):491-6. doi: 10.1021/ml300410d. eCollection 2013 May 9.

12.
13.

Impact of fibroblast activation protein on osteosarcoma cell lines in vitro.

Ding L, Ye L, Xu J, Jiang WG.

Oncol Lett. 2014 Mar;7(3):699-704. Epub 2014 Jan 10.

14.

Insidious changes in stromal matrix fuel cancer progression.

Miles FL, Sikes RA.

Mol Cancer Res. 2014 Mar;12(3):297-312. doi: 10.1158/1541-7786.MCR-13-0535. Epub 2014 Jan 22. Review.

15.

Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Poplawski SE, Lai JH, Li Y, Jin Z, Liu Y, Wu W, Wu Y, Zhou Y, Sudmeier JL, Sanford DG, Bachovchin WW.

J Med Chem. 2013 May 9;56(9):3467-77. doi: 10.1021/jm400351a. Epub 2013 Apr 29.

16.

Cancer-associated fibroblasts as targets for immunotherapy.

Kakarla S, Song XT, Gottschalk S.

Immunotherapy. 2012 Nov;4(11):1129-38. doi: 10.2217/imt.12.112. Review.

17.

Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.

Zhang J, Valianou M, Simmons H, Robinson MK, Lee HO, Mullins SR, Marasco WA, Adams GP, Weiner LM, Cheng JD.

FASEB J. 2013 Feb;27(2):581-9. doi: 10.1096/fj.12-210377. Epub 2012 Oct 26.

18.

The pharmacological landscape and therapeutic potential of serine hydrolases.

Bachovchin DA, Cravatt BF.

Nat Rev Drug Discov. 2012 Jan 3;11(1):52-68. doi: 10.1038/nrd3620. Review.

19.

Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma.

Hua X, Yu L, Huang X, Liao Z, Xian Q.

Diagn Pathol. 2011 Nov 8;6:111. doi: 10.1186/1746-1596-6-111.

20.

FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells.

Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, Cheng JD.

BMC Cancer. 2011 Jun 13;11:245. doi: 10.1186/1471-2407-11-245.

Supplemental Content

Support Center